BXCL501, a novel therapy developed for the acute treatment of agitation related with dementia.
BXCL501 is an investigational orally dissolving thin film formulation of dexmedetomidine for the treatment of agitation in patients with bipolar disorders, schizophrenia and dementia. It targets agitation mechanism by giving anti-agitation results in various neuropsychiatric disorders.
Sympotoms such as psychological and agitation behaviour are often seen in 70 per cent of patients affected with Dementia. In addition, it has the negative impact on the patient and caregiver's quality of life.
Since there are no FDA approved therapies, treatment for agitation in elderly patients has become a challenge. U.S. Food and Drug Administration (FDA) has approved BXCL501 for the treatment of agitation related to Dementia.
Dementia is a neurocognitive condition causing damage to the brain cells leading to weakening of cognitive abilities and independent functioning of the brain.
In U.S, it is estimated that approximately 6 million people are affected with Alzheimer's disease accounting up to 80% of these cases.
